Patent US6929633B2 successfully refreshed from Google Patents.
US6929633B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Apparatus and methods for clot dissolution
Assignee: Covidien LP
•
Filing: 2002-10-21
•
Granted: 2005-08-16
•
Expires: 2022-10-21
Abstract
Abstract Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, agitate the clot and agent, and aspirate broken-up clot from the blood vessel. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.
Inventors
- 👤 Michael A. Evans
- 👤 Denise Demarais
- 👤 Dino De Cicco
- 👤 Kelvin Ning
- 👤 Alexander Khairkhahan
- 👤 Tyler Jon Strang
- 👤 Jody Maria Cimbalo
- 👤 Stephen Leeflang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 08:20
CPC Classifications
A; A61; A61B; A61B17/00; A61B17/32; A61B17/3205; A61B17/3207; A61B17/320758; A61B17/22; A61M; A61M25/00; A61M25/0021; A61P; A61P9/00; A61B17/22004; A61B2017/00681; A61B2017/00685; A61B2017/22051; A61B2017/22054; A61B2017/22065; A61B2017/22067; A61B2017/22082; A61B2017/22084; A61B2017/320716; A61B2017/320766; A61M25/10; A61M2025/1043; A61M2025/1052; A61M25/0067; A61M25/0068; A61M25/007; A61M25/0074; A61M25/0075; A61M25/01; A61M25/0105; A61M39/00; A61M39/22
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
87 words
A method for disrupting clot over a luminal length of a blood vessel, said method comprising: positioning a catheter body within the luminal length of the blood vessel; infusing a thrombolytic agent through a lumen of the catheter body into the luminal length of the blood vessel; expanding an agitator within the catheter body to eccentrically deform a portion of the body; and rotating the agitator to sweep the catheter body within the luminal length of the blood vessel to agitate the thrombolytic agent within the clot.
Claim 2
Independent Claim
87 words
A method for disrupting clot over a luminal length of a blood vessel, said method comprising: positioning a catheter body within the luminal length of the blood vessel; infusing a thrombolytic agent through a lumen of the catheter body into the luminal length of the blood vessel; expanding an agitator within the catheter body to eccentrically deform a portion of the body; and rotating the agitator to sweep the catheter body within the luminal length of the blood vessel to agitate the thrombolytic agent within the clot.
Claim 3
Dependent Claim
20 words
A method as in claim 1 , wherein positioning the catheter body includes passing the catheter body over a guidewire.
Claim 4
Dependent Claim
18 words
A method as in claim 1 , wherein the catheter is rotated at a frequency of 1-20,000 Hertz.
Claim 5
Dependent Claim
28 words
A method as in claim 1 , wherein the agitator is resilient and radially self-expanding so that it is constrained by the blood vessel as it is rotated.
Claim 6
Dependent Claim
16 words
A method as in claim 4 , wherein the agitator has a non-linear geometry when expanded.
Claim 7
Dependent Claim
16 words
A method as in claim 1 , wherein the luminal length is at least 3 cm.
Claim 8
Dependent Claim
14 words
A method as in claim 1 , wherein the blood vessel is a vein.
Claim 9
Dependent Claim
36 words
A method as in claim 7 , wherein the vein is selected from the group consisting of vena cava, iliac vein, femoral vein, popliteal vein, common iliac vein, external iliac vein, brachial vein, and subclavian vein.
Claim 10
Dependent Claim
14 words
A method as in claim 1 , wherein the blood vessel is an artery.
Claim 11
Dependent Claim
35 words
A method as in claim 9 , wherein the artery is selected from the group consisting of the internal iliac artery, external iliac artery, popliteal artery, coronary arteries, superficial femoral artery, and the brachial artery.
Claim 12
Dependent Claim
22 words
A method as in claim 1 , further comprising isolating at least one end of the luminal length of the blood vessel.
Claim 13
Dependent Claim
22 words
A method as in claim 11 , further comprising isolating both a proximal end and a distal end of the luminal length.
Claim 14
Dependent Claim
16 words
A method as in claim 11 , wherein isolating comprises inflating at least one occlusion balloon.
Claim 15
Dependent Claim
21 words
A method as in claim 11 , wherein isolating at least a distal end is performed prior to infusing the agent.
Claim 16
Dependent Claim
21 words
A method as in claim 14 , wherein isolating at least one distal end is maintained until after agitating has stopped.
Claim 17
Dependent Claim
22 words
A method as in claim 1 , further comprising aspirating disrupted clot material from along the luminal length of the blood vessel.
Claim 18
Dependent Claim
25 words
A method as in claim 16 , wherein aspirating disrupted clot and infusing the agent are performed through a common lumen in the catheter body.
References Cited (Backward Citations)
US4573966A
Cited
US4445509A
Cited
US5190546A
Cited
US5067957A
Cited
US4646736A
Cited
US4923462A
Cited
US4794928A
Cited
US5059178A
Cited
US5116352A
Cited
US5222941A
Cited
US5163905A
Cited
US5041093A
Cited
US5135484A
Cited
US5279546A
Cited
US5330484A
Cited
US5596005A
Cited
US5284486A
Cited
US5569275A
Cited
US5766191A
Cited
US5176693A
Cited
US5498236A
Cited
US5380273A
Cited
US5360432A
Cited
US5312427A
Cited
US5356418A
Cited
US5836868A
Cited
US5490859A
Cited
US5501694A
Cited
US5540707A
Cited
US5709874A
Cited
US5897567A
Cited
US5713848A
Cited
US5419774A
Cited
US5417703A
Cited
US5370653A
Cited
US5462529A
Cited
US5410093A
Cited
US5507795A
Cited
WO1996001591A1
Cited
US5549119A
Cited
US5554114A
Cited
US5584843A
Cited
US5876414A
Cited
US5873882A
Cited
US5795322A
Cited
US5556408A
Cited
US5674198A
Cited
US5758656A
Cited
WO1997011738A1
Cited
US5643228A
Cited
US5972019A
Cited
US5843103A
Cited
US6156048A
Cited
US5951514A
Cited
US5908395A
Cited
US6063069A
Cited
US5904698A
Cited
WO1999004701A1
Cited
US5928203A
Cited
US6179816B1
Cited
US5957901A
Cited
US6156046A
Cited
WO1999023952A1
Cited
US5947985A
Cited
US6027514A
Cited
US5954737A
Cited
US6295990B1
Cited
US6146395A
Cited
US6113614A
Cited
US6090118A
Cited
US6036708A
Cited
WO2000041762A1
Cited
US6322572B1
Cited
US6454775B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2008-08-15 | 2009-02-14 | 2009-08-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2012-08-15 | 2013-02-14 | 2013-08-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2016-08-15 | 2017-02-14 | 2017-08-16 | $7700.00 | Window Closed / Lapsed |